Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space |
Nkarta Inc. NKTX on Wednesday reported a first-quarter loss of 43 cents per share, beating the consensus loss of 44 cents. |
benzinga.com |
2025-05-15 19:46:39 |
Czytaj oryginał (ang.) |
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights |
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter and year ended March 31, 2025. |
globenewswire.com |
2025-05-14 20:01:00 |
Czytaj oryginał (ang.) |
Nkarta (NKTX) Upgraded to Buy: Here's Why |
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-04-14 17:00:41 |
Czytaj oryginał (ang.) |
Nkarta to Participate in an April Investor Conference |
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: |
globenewswire.com |
2025-04-01 12:01:00 |
Czytaj oryginał (ang.) |
Nkarta: Grinding Lower, Trying To Find Support |
Nkarta, Inc. has provided significant pipeline updates, showcasing promising advancements in their innovative cell therapy treatments. A financial overview highlights a robust balance sheet, with sufficient cash reserves to support ongoing research and development activities. Strengths include cutting-edge technology and strategic partnerships, while risks involve clinical trial uncertainties and regulatory hurdles. |
seekingalpha.com |
2025-03-31 14:41:35 |
Czytaj oryginał (ang.) |
Nkarta: Betting On The Turnaround |
Nkarta's NKX019 shows promise in treating autoimmune diseases, despite a 70% stock drop; strategic restructuring extends financial runway to 2029. Q4 and full-year 2024 earnings reveal significant R&D expenses and a net loss, but a strong cash position of $380.5M. Upcoming clinical data from Ntrust-1 and Ntrust-2 trials are key catalysts; positive results could validate NKX019 and attract investor attention. |
seekingalpha.com |
2025-03-31 14:15:30 |
Czytaj oryginał (ang.) |
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? |
Nkarta, Inc. NKTX reported a fourth-quarter earnings report on Wednesday with a loss of 35 cents per share, beating the consensus of a loss of 41 cents. |
benzinga.com |
2025-03-27 14:50:30 |
Czytaj oryginał (ang.) |
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights |
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestones Cash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2024. |
globenewswire.com |
2025-03-26 18:01:00 |
Czytaj oryginał (ang.) |
Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
The heavy selling pressure might have exhausted for Nkarta (NKTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-03-20 12:35:22 |
Czytaj oryginał (ang.) |
Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
Nkarta (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-03-19 12:35:18 |
Czytaj oryginał (ang.) |
Nkarta to Participate in March Investor Conferences |
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences: |
globenewswire.com |
2025-02-25 10:01:00 |
Czytaj oryginał (ang.) |
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2 |
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts |
globenewswire.com |
2024-12-05 08:01:00 |
Czytaj oryginał (ang.) |
Nkarta to Participate in an Upcoming Investor Conference |
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: |
globenewswire.com |
2024-11-26 09:02:00 |
Czytaj oryginał (ang.) |
Nkarta to Participate in an Upcoming Investor Conference |
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: |
globenewswire.com |
2024-11-12 10:02:00 |
Czytaj oryginał (ang.) |
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights |
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the third quarter ended September 30, 2024. |
globenewswire.com |
2024-11-07 18:02:00 |
Czytaj oryginał (ang.) |
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month |
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. |
benzinga.com |
2024-10-08 13:07:20 |
Czytaj oryginał (ang.) |
Nkarta to Participate in Upcoming Investor Conference |
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: |
globenewswire.com |
2024-09-03 20:01:00 |
Czytaj oryginał (ang.) |
Why Nkarta Stock Is Soaring Today |
Raymond James upgraded Nkarta stock from outperform to a strong buy. The investment firm likes the biopharma's cash position and the opportunities for its lead candidate NKX019. |
fool.com |
2024-08-14 16:37:31 |
Czytaj oryginał (ang.) |
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights |
This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three doses of NKX019 on Days 0, 7, and 14. |
globenewswire.com |
2024-08-14 01:03:00 |
Czytaj oryginał (ang.) |
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights |
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2024. |
globenewswire.com |
2024-08-13 20:01:00 |
Czytaj oryginał (ang.) |
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President |
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. |
globenewswire.com |
2024-07-16 10:01:00 |
Czytaj oryginał (ang.) |
Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know |
Nkarta (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-07-10 17:00:32 |
Czytaj oryginał (ang.) |
3 Undervalued Stocks Primed for a 2X Return |
For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan. |
investorplace.com |
2024-07-01 14:20:00 |
Czytaj oryginał (ang.) |
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications |
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis |
globenewswire.com |
2024-06-27 10:00:00 |
Czytaj oryginał (ang.) |
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors |
Senior R&D leader brings extensive expertise in immunology, clinical development and translational science Senior R&D leader brings extensive expertise in immunology, clinical development and translational science |
globenewswire.com |
2024-06-13 20:01:00 |
Czytaj oryginał (ang.) |
Nkarta: Finally An Attractive Valuation |
Nkarta Inc. is using natural killer cells engineered with CARs and membrane-bound IL-15 to target autoimmune diseases and oncology. The company's off-the-shelf availability and superior safety profile make it an attractive option for patients, providers, and payers. Nkarta is targeting large markets, such as lupus nephritis and non-Hodgkin lymphoma, with the potential to produce blockbuster therapies. |
seekingalpha.com |
2024-05-25 06:20:02 |
Czytaj oryginał (ang.) |
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights |
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter ended March 31, 2024. |
globenewswire.com |
2024-05-09 20:01:00 |
Czytaj oryginał (ang.) |
Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's Radar |
Three equities stand out among the plethora of alternatives as possible Wall Street game-changers. Each represents a distinct industry: energy, cannabis and biotechnology. |
investorplace.com |
2024-05-07 10:30:00 |
Czytaj oryginał (ang.) |
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead |
NKTX is now down over 50% from its March 2024 highs. The company's pipeline includes NKX019, a CAR-NK cell therapy with potential in cancer and autoimmune disease. NKTX has already produced some data with NKX019 in oncology with more data coming mid-year. The work in autoimmune disease is just getting underway in H1'24. |
seekingalpha.com |
2024-04-27 14:27:00 |
Czytaj oryginał (ang.) |
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors |
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nkarta, Inc. (“Nkarta” or the “Company”) (NASDAQ: NKTX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Nkarta investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you. |
businesswire.com |
2024-04-08 16:55:00 |
Czytaj oryginał (ang.) |
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors |
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Nkarta, Inc. (“Nkarta” or the “Company”) (NASDAQ: NKTX) investors concerning the Company's possible violations of federal securities laws. On March 21, 2024, Nkarta announced that it had “deprioritized” its acute myeloid leukemia program, NKX101, stating that the “response rate was meaningfully lower than that from the first 5 previously reported patients.” On this news, Nkarta's stock price f. |
businesswire.com |
2024-04-05 21:44:00 |
Czytaj oryginał (ang.) |